Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products - FDA Press Releases

FDA updates draft guidance to set a clear path for the nonproprietary naming of interchangeable biosimilars.

from Food and Drug Administration--Press Releases https://ift.tt/2SQM8HI
via IFTTT